

Please complete all required sections to allow your request to be processed.

PATIENT INFORMATION				COVERAGE TYPE
PATIENT LAST NAME	FIRST NAME	INITIAL		<input type="checkbox"/> Alberta Blue Cross <input type="checkbox"/> Alberta Human Services <input type="checkbox"/> Other _____
BIRTH DATE (YYYY-MM-DD)	ALBERTA PERSONAL HEALTH NUMBER			
ADDRESS	CITY	PROVINCE	POSTAL CODE	ID/CLIENT/COVERAGE NUMBER

PRESCRIBER INFORMATION				
PRESCRIBER LAST NAME	FIRST NAME	INITIAL	PRESCRIBER PROFESSIONAL ASSOCIATION REGISTRATION	
ADDRESS			<input type="checkbox"/> CPSA	<input type="checkbox"/> ACO
			<input type="checkbox"/> CARNA	<input type="checkbox"/> ADA+C
			<input type="checkbox"/> ACP	<input type="checkbox"/> Other
CITY	PROVINCE	PHONE	FAX	
POSTAL CODE	FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED			

CCB products* that are subject to MAC and LCA pricing on the iDBL. MAC pricing will be applied as follows effective December 12, 2019.

Active ingredient	Strength/Form	LCA/MAC price	
FELODIPINE	2.5 MG, 5 MG & 10 MG ORAL EXTENDED-RELEASE TABLET	\$0.1993	<i>MAC pricing has been applied based on the LCA price for Amlodipine Besylate 1 X 10 mg tablet.</i>
NIFEDIPINE	20 MG, 30 MG & 60 MG ORAL EXTENDED-RELEASE TABLET		
AMLODIPINE BESYLATE	2.5 MG, 5 MG & 10 MG ORAL TABLET	<i>These products are not affected by MAC pricing. Least cost alternative pricing will continue to apply.</i>	

*Please refer to the iDBL for a full listing of CCB products.

Pricing authorization request where the patient is unable to use the MAC reference product

1) Select CCB and indicate if the corresponding MAC reference product has been used.

Requested CCB (please check one).	Has the patient used the MAC reference product for the requested CCB?
<input type="checkbox"/> felodipine 2.5 mg, 5 mg & 10 mg <input type="checkbox"/> nifedipine extended release 20 mg, 30 mg & 60 mg	<input type="checkbox"/> Yes, amlodipine besylate was used. <input type="checkbox"/> No, amlodipine besylate was not used. Please specify reasons. _____

2) If the patient has used the MAC reference product for the requested CCB, what was the response?

- Therapeutic failure of the MAC reference product. Please specify diagnosis. _____
- Adverse effects. Please elaborate on the nature and severity of the adverse effects experienced by your patient on the MAC reference product. _____
- Has the patient used the MAC reference product for a sufficient duration to determine that the adverse effects will not resolve over time?
 Yes No

Additional information relating to request

PRESCRIBER'S SIGNATURE	DATE (YYYY-MM-DD)	Please forward this request to Alberta Blue Cross, Clinical Drug Services 10009 108 Street NW, Edmonton, Alberta T5J 3C5 FAX: (780) 498-8384 in Edmonton • 1-877-828-4106 toll free all other areas
------------------------	-------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ONCE YOUR REQUEST HAS SUCCESSFULLY TRANSMITTED, PLEASE DO NOT MAIL OR RE-FAX YOUR REQUEST.



Frequently asked questions**1. What is the difference between LCA and MAC pricing?**

The **Least Cost Alternative (LCA) price** means the maximum amount that will be paid by the Government of Alberta for a drug product in an established or new interchangeable grouping for members of a plan. For example, Plendil 10 mg is in a grouping with generic brands of felodipine 10 mg that are interchangeable with brand name Plendil 10 mg. The maximum unit price paid for Plendil 10 mg is thus based on the lowest-priced generic interchangeable product within the grouping.

A **MAC grouping** means a grouping of drug products that have been listed on the *Alberta Drug Benefit List (ADBL)* as being subject to a maximum price. Note that a MAC grouping may include one or more groupings of interchangeable drugs. For example, CCB products have been grouped together such that the maximum unit price paid for select CCB products (felodipine 2.5 mg, 5 mg & 10 mg, nifedipine extended release 20 mg, 30 mg & 60 mg) will be based on the cost of amlodipine besylate 10 mg, which is \$0.1993 per unit (tablet).

2. What happens if a product is subject to both LCA and MAC pricing?

If a product is subject to both MAC and LCA pricing, the maximum unit price paid for the Drug Product will be based on the unit cost of the product that establishes the MAC grouping. For example, Adalat XL 30 mg is subject to both LCA and MAC pricing and as such, the maximum unit price paid will be based on the product that establishes the MAC grouping; in this case, amlodipine besylate 10 mg, which is \$0.1993 per unit (tablet).